More Information Product Details Synonyms Product Type Properties Clone Isotype Immunogen/Antigen Label/Conjugates Application Crossreactivity Specificity Purity Concentration Formulation Accession Number Shipping and Handling Shipping Short Term Storage Long Term Storage Handling Advice Use/Stability Documents MSDS Product Specification Sheet Datasheet

Toll-like Receptor 7

Monoclonal Antibody

ABM2C27

Mouse IgG1κ

Recombinant human TLR7 protein (aa 500-900).

FITC

Flow Cytometry: (0.5μg/106 cells)Optimal conditions must be determined individually for each application.

Human

Recognizes human TLR7.

Protein G purified.

0.2mg/ml

Liquid. In 10mM TRIS containing 150mM NaCl and 0.05% sodium azide.

Q9NYK1

BLUE ICE

+4°C

+4°C

Do not freeze.Protect from light.

Stable for at least 6 months after receipt when stored at +4°C.

No

Download PDF

TLR7 (Toll-like Receptor 7) is a member of the TLR (Toll-like receptor) family that plays a fundamental role in pathogen recognition and activation of innate immunity. TLR7 is a nucleotide-sensing TLR. TLR7 and TLR8 recognize single-stranded RNA (ssRNA) sequences containing GU-rich or poly-U sequences as their natural ligands, and they are also activated by synthetic small-molecular-weight compounds of the imidazoquinoline family. Both TLR7 and TLR8 signal via MYD88 and TRAF6, leading to NF-κB and antiviral factor, such as IRF family activation, cytokine secretion and the inflammatory response. They are localized intracellularly to endosomal membranes and act as potent activators of innate immune responses upon viral infection. The TLR7 gene is predominantly expressed in lung, placenta and spleen, and lies in close proximity to TLR8 on chromosome X. TLR7 has been shown to play a significant role in the pathogenesis of autoimmune disorders such as Systemic Lupus Erythematosus (SLE) as well as in the regulation of antiviral immunity. Recently, small molecule TLR7/8 agonists have demonstrated potential as vaccine adjuvants, since they directly activate APCs and can enhance both humoral and cellular immune responses, especially Th1 responses. This makes the TLR7/8 signaling pathways interesting therapeutic targets.